Amarin Corporation plc AMRN, a biopharmaceutical company focused on
the commercialization and development of therapeutics to improve
cardiovascular health, announced today that the United States Patent and
Trademark Office (USPTO) has published notification of Notice of Allowance for
U.S. Patent Application Serial Number 13/623,450. This application includes
claims intended to protect the Vascepa^® (icosapent ethyl) indication approved
by the U.S. Food and Drug Administration (FDA) based on Amarin's MARINE
clinical trial results.
A Notice of Allowance is issued after the USPTO makes a determination that a
patent can be granted from an application. The issued patent would have a term
that expires no earlier than in 2030. After issuance, Amarin plans to list
this patent in the FDA's Approved Drug Products with Therapeutic Equivalence
Evaluations, or Orange Book.
The claims in this allowed application cover a method of use relating to
Vascepa's MARINE indication. Specifically, the allowed independent claim
covers use of highly pure icosapent ethyl, or EPA, including Vascepa, in
lowering triglycerides regardless of the drug's effect on LDL-C levels.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in